Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The decision marks a pivotal moment for the Massachusetts-based biotech giant
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
